EudraLex directives and variations/extensions MCQs With Answer
This quiz collection is designed for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics (MRA201T). It focuses on EudraLex — the body of European pharmaceutical legislation and guidance — and the regulatory processes for post-authorisation changes, including classifications of variations and extensions. The questions cover the structure of EudraLex, key directives, the classification and practical examples of Type IA/IB/II variations, line extensions, and regulatory procedures under national, mutual recognition and centralised routes. Each item tests conceptual understanding and real-world application so students can confidently handle regulatory submissions, variation classification and decide when an extension or a full application is required.
Q1. What is EudraLex in the context of European pharmaceutical regulation?
- A legal and guidance collection covering EU laws, guidelines and procedures for medicinal products
- A pharmacopoeial monograph compilation for Europe
- An EMA database of clinical trial results only
- A GMP inspection schedule list for European manufacturers
Correct Answer: A legal and guidance collection covering EU laws, guidelines and procedures for medicinal products
Q2. Which volume of EudraLex contains the EU Guidelines for Good Manufacturing Practice (GMP)?
- Volume 1
- Volume 2
- Volume 3
- Volume 4
Correct Answer: Volume 4
Q3. Which Directive is the primary legal framework for medicinal products for human use in the EU?
- Directive 2001/83/EC
- Directive 2010/84/EU
- Directive 2003/94/EC
- Directive 98/79/EC
Correct Answer: Directive 2001/83/EC
Q4. How are post-authorisation changes to a marketing authorisation commonly classified under EU regulatory practice?
- Minor and Major only
- Type I, Type II and Type III
- Type IA, Type IB and Type II
- Administrative and Scientific
Correct Answer: Type IA, Type IB and Type II
Q5. Which variation type generally requires prior regulatory approval before implementation?
- Type IA
- Type IB
- Type II
- Administrative notification only
Correct Answer: Type II
Q6. Which variation type is typically described as a “do-and-tell” change that the marketing authorisation holder can implement immediately and then notify the authority?
- Type II
- Type IB
- Type IA
- Extension application
Correct Answer: Type IA
Q7. A change that affects a critical manufacturing step and could impact product quality and efficacy should be classified as which of the following?
- Type IA minor administrative change
- Type IB minor quality tweak with no review
- Type II major variation requiring prior approval
- No notification required
Correct Answer: Type II major variation requiring prior approval
Q8. The addition of a new pharmaceutical strength to an existing marketing authorisation is best described as:
- An administrative change that never needs data
- A line extension (extension) that often requires substantial supporting data or classification as a major change
- A Type IA change implemented immediately
- A purely packaging change
Correct Answer: A line extension (extension) that often requires substantial supporting data or classification as a major change
Q9. In regulatory terminology, what does an “extension” to a marketing authorisation typically mean?
- Only a change to the manufacturer’s internal quality system
- An expansion of the authorised product scope such as new indication, strength, form or route
- A renewal of the authorisation validity period
- Removal of a minor excipient from the formulation
Correct Answer: An expansion of the authorised product scope such as new indication, strength, form or route
Q10. Which body or document provides the primary guidance on classification of variations in the EU?
- European Commission guidance on classification of variations
- National pharmacopoeia only
- Individual company SOPs without regulatory input
- World Health Organization GMP Annexes
Correct Answer: European Commission guidance on classification of variations
Q11. For centrally authorised products, which agency coordinates the assessment of variation applications?
- The national competent authority of the marketing authorisation holder
- The World Health Organization
- The European Medicines Agency (EMA)
- The European Court of Justice
Correct Answer: The European Medicines Agency (EMA)
Q12. Which statement best describes a Type IB variation?
- It is a major change requiring prior approval and full dossier submission
- It is a minor change that requires notification to authorities and is not considered immediately implementable without following specific rules
- It is an administrative labeling correction only
- It is an extension involving a new indication
Correct Answer: It is a minor change that requires notification to authorities and is not considered immediately implementable without following specific rules
Q13. What is the regulatory difference between a renewal and a variation?
- Renewal updates product chemistry; variation always renews the MA
- Renewal is a periodic confirmation of the authorisation validity; variation is a post-authorisation change to the terms of the authorisation
- There is no difference; both are identical procedures
- Variation only happens at initial approval; renewal only for generics
Correct Answer: Renewal is a periodic confirmation of the authorisation validity; variation is a post-authorisation change to the terms of the authorisation
Q14. Which of the following would typically be classified as a Type IA (minor) change?
- Major change to the therapeutic indication backed by new clinical studies
- Typographical corrections to the SmPC that do not alter meaning
- Change of the manufacturing plant for the active substance affecting a critical step
- Addition of a new strength or dosage form
Correct Answer: Typographical corrections to the SmPC that do not alter meaning
Q15. Which committee within EMA is commonly involved in assessment of major variations for centrally authorised medicines?
- Pharmacovigilance Risk Assessment Committee (PRAC)
- Committee for Herbal Medicinal Products (HMPC)
- Committee for Medicinal Products for Human Use (CHMP)
- Orphan Medicinal Products Committee (COMP)
Correct Answer: Committee for Medicinal Products for Human Use (CHMP)
Q16. What is meant by a “line extension” in EU regulatory practice?
- Minor label wording change
- Introduction of a new formulation, strength, route or indication within the same product family
- Administrative transfer of MAH only
- Change in GMP inspection frequency
Correct Answer: Introduction of a new formulation, strength, route or indication within the same product family
Q17. Under what circumstances might an extension be handled as a new marketing authorisation rather than a variation?
- When the change is only a minor spelling correction
- When the extension significantly alters safety, efficacy or creates a product sufficiently different to require full dossier and independent assessment
- When the MAH prefers faster processing
- When the change is purely administrative and cosmetic
Correct Answer: When the extension significantly alters safety, efficacy or creates a product sufficiently different to require full dossier and independent assessment
Q18. Which types of supporting data are commonly required for a quality-related Type II variation?
- Updated CMC dossier, stability data, validation reports and risk assessment
- Only a one-line statement from the manufacturer
- Marketing materials and sales forecasts
- Clinical study protocols unrelated to the change
Correct Answer: Updated CMC dossier, stability data, validation reports and risk assessment
Q19. What does PASS stand for in the post-authorisation regulatory context?
- Post-Authorisation Safety Study
- Pre-Authorisation Scientific Submission
- Product Approval and Safety Survey
- Pharmacovigilance Administrative Submission Schedule
Correct Answer: Post-Authorisation Safety Study
Q20. Which statement is true regarding implementation of Type II variations?
- They can be implemented immediately and notified later
- They generally require prior approval and must not be implemented until authorised
- They never require any supporting data
- They are only relevant to veterinary products
Correct Answer: They generally require prior approval and must not be implemented until authorised
